Top

Published in:

01-06-2018 | Short Communication

Cardiovascular profile improvement during Natalizumab treatment

Authors: Marcello Moccia, Roberto Albero, Roberta Lanzillo, Francesco Saccà, Anna De Rosa, Cinzia Valeria Russo, Antonio Carotenuto, Raffaele Palladino, Vincenzo Brescia Morra

Published in: Metabolic Brain Disease | Issue 3/2018

Abstract

Cardiovascular comorbidities are associated with the risk of MS progression. Thus, we aim to measure variations of cardiovascular risk factors during Natalizumab treatment and their possible clinical associations. Seventy-one relapsing-remitting MS patients treated with Natalizumab were followed-up during a 12.9 ± 6.2 months. Cardiovascular risk factors were recorded on first and last study visits: systolic blood pressure, uric acid, total cholesterol, LDL, HDL, and triglycerides. EDSS progression and relapse occurrence were recorded. At multilevel mixed-effects linear regression models, the population presented with a significant reduction of total cholesterol (Coeff = −7.340; 95%CI = −13.152--1.527; p = 0.013), and of HDL cholesterol (Coeff = −3.473; 95%CI = −6.333--0.613; p = 0.017), and a non-significant reduction of LDL cholesterol (Coeff = −1.872; 95%CI = −8.481–0.736; p = 0.053), and of triglycerides (Coeff = −8.815; 95%CI = −34.011–5.380; p = 0.094). Uric acid levels increased during the study period (Coeff = 0.159; 95%CI = 0.212–0.340; p = 0.038). No significant associations were found with clinical outcomes. Serum lipids decreased and anti-oxidant uric acid increased during Natalizumab treatment. These biomarkers need to be further explored in relation to clinical outcomes on larger cohorts with longer follow-ups.

Brescia Morra V, Coppola G, Orefice G, De Michele G, Vacca G, Filla A et al (2004) Interferon-b treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology 62(5):829–830. https://doi.org/10.1212/01.WNL.0000113750.11090.67 CrossRefPubMed

Cerda A, Rodrigues AC, Alves C, Dalla F, Genvigir V, Fajardo CM et al (2015) Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from Hypercholesterolemic patients. Cardiovasc Ther 33(4):168–176. https://doi.org/10.1111/1755-5922.12126 CrossRefPubMed

Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CRM, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R (2014) Eff ect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383(9936):2213–2221. https://doi.org/10.1016/S0140-6736(13)62242-4 CrossRefPubMed

Hon G, Hassan M, van Rensburg S, Abel S, Erasmus R, Matsha T (2009) Membrane saturated fatty acids and disease progression in multiple sclerosis patients. Metab Brain Dis 24(4):561–568. https://doi.org/10.1007/s11011-009-9159-0 CrossRefPubMed

Jorissen W, Wouters E, Bogie JF, Vanmierlo T, Noben J, Sviridov D et al (2017) Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep 7:43410. https://doi.org/10.1038/srep43410 CrossRefPubMedPubMedCentral

Kappus N, Weinstock-guttman B, Hagemeier J, Kennedy C, Melia R, Carl E et al (2016) Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(2):181–187. https://doi.org/10.1136/jnnp-2014-310051 PubMedCrossRef

Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, de Rosa A, Brescia Morra V (2017) A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand 136(3):217–222. https://doi.org/10.1111/ane.12718 CrossRefPubMed

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 16(4):450–454. https://doi.org/10.1177/1352458509358909 CrossRefPubMed

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter GA (2015) Systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 21(3):318–331. https://doi.org/10.1177/1352458514564485 CrossRefPubMedPubMedCentral

Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, de Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V (2015a) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262(4):961–967. https://doi.org/10.1007/s00415-015-7666-y CrossRefPubMed

Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V (2015b) The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol 22(8):1176–1183. https://doi.org/10.1111/ene.12720 CrossRefPubMed

Novakova L, Axelsson M, Malmeström C, Zetterberg H, Björkhem I, Karrenbauer VD, Lycke J (2015) Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. J Neurol Sci 358(1–2):201–206. https://doi.org/10.1016/j.jns.2015.08.1537 CrossRefPubMed

Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D, Kollar B (2015) Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 30(4):895–901. https://doi.org/10.1007/s11011-015-9665-1 CrossRefPubMed

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366 CrossRefPubMedPubMedCentral

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS (2008) Ethics of placebo-controlled clinical trials in multiple sclerosis. Neurology 70(Issue 13, Part 2):1134–1140. https://doi.org/10.1212/01.wnl.0000306410.84794.4d CrossRefPubMed

Solomon AJ, Bernat JLA (2016) Review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics. Mult Scler Relat Disord 7:109–112. https://doi.org/10.1016/j.msard.2016.03.019 CrossRefPubMed

Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D (2014) Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther 32(2):33–39. https://doi.org/10.1111/1755-5922.12049 CrossRefPubMed

Tettey P, Jr SS, Taylor B, Blizzard L, Ponsonby A, Dwyer T et al (2014) An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 20(13):1737–1744. https://doi.org/10.1177/1352458514533162 CrossRefPubMed

Tettey P, Simpson S, Taylor B, Ponsonby A, Lucas R, Dwyer T et al (2017) An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. J Neurol Neurosurg Psychiatry 88(5):395–401

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M (2017) Serum lipid profile changes predict neurodegeneration in interferon-B1a treated multiple sclerosis patients. J Lipid Res 58(2):403–411. https://doi.org/10.1194/jlr.M072751 CrossRefPubMedPubMedCentral

Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M (2013) Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 84(11):1186–1191. https://doi.org/10.1136/jnnp-2012-304740 CrossRefPubMed

Zhornitsky S, Mckay KA, Metz LM, Teunissen CE (2016) Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Mult Scler Relat Disord 5:53–65. https://doi.org/10.1016/j.msard.2015.10.005 CrossRefPubMed

Title: Cardiovascular profile improvement during Natalizumab treatment
Authors: Marcello Moccia
Roberto Albero
Roberta Lanzillo
Francesco Saccà
Anna De Rosa
Cinzia Valeria Russo
Antonio Carotenuto
Raffaele Palladino
Vincenzo Brescia Morra
Publication date: 01-06-2018
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 3/2018
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-017-0169-z

At a glance: The STEP trials

Springer Medicine

Cardiovascular profile improvement during Natalizumab treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Association between PDE4D rs966221 polymorphism and risk of ischemic stroke: a systematic review and meta-analysis

Relationship between absolute and relative ratios of glutamate, glutamine and GABA and severity of autism spectrum disorder

The possible factors affecting microglial activation in cases of obesity with cognitive dysfunction

Vanillic acid attenuates cerebral hyperemia, blood-brain barrier disruption and anxiety-like behaviors in rats following transient bilateral common carotid occlusion and reperfusion

Late-onset cobalamin C deficiency Chinese sibling patients with neuropsychiatric presentations

ER stress and genomic instability induced by gamma radiation in mice primary cultured glial cells